Does Rallies show 13F holders for PALI?

Yes. Rallies tracks hedge fund and 13F ownership data for PALI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PALI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PALI. It does not provide personalized investment advice.

PALI (Palisade Bio, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Palisade Bio, Inc. Common Stock (PALI) is a publicly traded Healthcare sector company. As of May 21, 2026, PALI trades at $1.87 with a market cap of $314.54M and a P/E ratio of -6.08. PALI moved +4.42% today. Year to date, PALI is -10.48%; over the trailing twelve months it is +155.12%. Its 52-week range spans $0.53 to $4.32. Analyst consensus is strong buy with an average price target of $10.67. Rallies surfaces PALI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PALI stock?

Hedge funds tracked by Rallies that own PALI include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Palisade Bio, Inc. Common Stock.

PALI Key Metrics

Key financial metrics for PALI
Metric	Value
Price	$1.87
Market Cap	$314.54M
P/E Ratio	-6.08
EPS	$-0.30
Dividend Yield	0.00%
52-Week High	$4.32
52-Week Low	$0.53
Volume	54
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-16.78M
Gross Margin	0.00%

Top Hedge Funds Holding PALI

Orbimed Advisors holds 2.33M shares of PALI, changed +24.66% as of Mar 31, 2026.

Latest PALI News

Palisade Bio Reports $132.6M Cash to Fund Phase 2 UC and CD Trials — May 12, 2026
Palisade Bio to Present PALI-2108 Phase 1 Ulcerative Colitis Data Showing Biomarker Gains — Apr 16, 2026
Palisade Bio’s PALI-2108 Sees 47.5% SES-CD Reduction, Advances to Phase 2 — Mar 30, 2026
Palisade Bio’s PALI-2108 Yields 63% UC Score Gain; $138M Runway Extends to 2029 — Mar 1, 2026

Recent PALI Insider Trades

Jones Mitchell Lawrence sold 1.99K (~$3.48K) on Feb 12, 2026.
Finley John David sold 3.90K (~$6.82K) on Feb 12, 2026.
Williams Donald Allen bought 5.00K (~$8.36K) on Jan 16, 2026.

PALI Analyst Consensus

6 analysts cover PALI: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.67.

Common questions about PALI

Who owns PALI stock?: Hedge funds tracked by Rallies that own PALI include Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Palisade Bio, Inc. Common Stock.
Does Rallies show 13F holders for PALI?: Yes. Rallies tracks hedge fund and 13F ownership data for PALI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PALI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PALI. It does not provide personalized investment advice.